What is the recommended dosing, contraindications, precautions, and alternative therapies for alfuzosin in adult men with benign prostatic hyperplasia?

Alfuzosin for Benign Prostatic Hyperplasia

Alfuzosin 10 mg once daily, taken immediately after the same meal each day, is the recommended dosing for adult men with BPH/LUTS, offering effective symptom relief with a favorable cardiovascular and sexual function safety profile. 1

Dosing

• Standard dose: 10 mg once daily as an extended-release tablet 1
• Must be taken immediately after the same meal each day (absorption is 50% lower under fasting conditions) 1
• Tablets must be swallowed whole—do not crush or chew 1
• No dose titration required, unlike terazosin or doxazosin 2, 3

Contraindications

Absolute contraindications include 1:

• Moderate or severe hepatic impairment (Child-Pugh categories B and C)—alfuzosin blood levels are significantly increased
• Concomitant use with potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir)
• Known hypersensitivity to alfuzosin hydrochloride or any tablet component

Key Precautions and Safety Considerations

Cardiovascular Effects

• Postural hypotension risk is low compared to other alpha-blockers due to alfuzosin's uroselectivity [4, @31@]
• Minimal blood pressure changes observed in clinical trials, including in elderly and hypertensive patients 5
• Patients should be counseled about possible dizziness (5.7% incidence) when initiating therapy and cautioned about driving or operating machinery during this period 1
• No dose titration needed reduces first-dose hypotensive risk 2

Sexual Function

• Ejaculatory disorders are rare (0.4-0.6% incidence), significantly lower than with other alpha-blockers like silodosin 1, 6, 7
• Priapism has been reported post-marketing 1

Ophthalmologic Considerations

• Intraoperative Floppy Iris Syndrome (IFIS) can occur during cataract surgery 1
• Patients must inform their ophthalmologist about alfuzosin use before any eye surgery, even if no longer taking the medication 1

Drug Interactions

• Avoid concurrent use with other alpha-blockers for either BPH or hypertension 1
• Exercise caution with antihypertensive medications, though alfuzosin shows minimal additional blood pressure effects 5, 7

Clinical Efficacy

Symptom Improvement

• IPSS improvement of approximately 6 points from baseline versus 4.2 points with placebo 5
• Peak flow rate increase of 2.3 mL/s versus 1.1 mL/s with placebo 5
• Efficacy is independent of prostate size, unlike 5-alpha-reductase inhibitors 4, 5
• Rapid onset: significant improvement observed within 14 days 5
• Sustained benefit: improvements maintained for up to 3 years in real-world practice 7

Acute Urinary Retention Management

• Alfuzosin 10 mg should be prescribed prior to trial without catheter (TWOC) in men with BPH-related AUR 4
• Administer for at least 2-3 days before attempting TWOC 4, 8
• Success rate of 60% versus 39% with placebo in pooled studies 4
• Patients should be informed of increased risk of recurrent retention even after successful TWOC 4

Alternative and Combination Therapies

Other Alpha-Blockers

• Tamsulosin 0.4 mg and silodosin 8 mg are alternatives with similar efficacy 4, 8
• Silodosin has the most favorable cardiovascular profile but highest rate of ejaculatory dysfunction 3
• Terazosin and doxazosin require dose titration and have higher cardiovascular side effect rates 4, 3

Combination Therapy

• Alpha-blocker plus 5-alpha-reductase inhibitor (finasteride or dutasteride) for men with prostate volume >30-40 mL to reduce long-term progression risk 4
• Alpha-blocker plus antimuscarinic (e.g., propiverine) for storage-predominant symptoms, though start with alpha-blocker monotherapy first 4, 6
• Alpha-blocker plus PDE5 inhibitor (e.g., tadalafil) may provide additional benefit for combined LUTS and erectile dysfunction 6
• Combination of alpha-blocker with tadalafil alone is not recommended over monotherapy due to higher side effects without superior symptom improvement 4

Non-Pharmacologic Options

• Watchful waiting appropriate for mild symptoms 4
• Behavioral modifications and self-management for uncomplicated LUTS 4
• Surgical intervention (TURP or minimally invasive procedures) for refractory symptoms, recurrent AUR, or complications 4

Common Pitfalls to Avoid

• Do not prescribe alfuzosin on an empty stomach—absorption is significantly reduced 1
• Do not combine with potent CYP3A4 inhibitors—this is an absolute contraindication 1
• Do not use in moderate-to-severe liver disease—drug levels become dangerously elevated 1
• Screen for planned cataract surgery—discontinuation may be considered to reduce IFIS risk 1
• Monitor post-void residual volume if considering combination with antimuscarinics to avoid urinary retention 4